Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs acti ...

Core Insights - Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for fibrotic diseases [1][4] - The company will participate in several investor events in September 2024, including the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference, and Stifel Virtual Immunology and Inflammation Summit [2] Company Overview - Pliant Therapeutics is recognized as a leader in the discovery and development of therapeutics for fibrotic diseases [4] - The lead product candidate, bexotegrast (PLN74809), is an oral small molecule that acts as a dual selective inhibitor of αvß6 and αvß1 integrins, targeting idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) [4] - Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the FDA for both IPF and PSC, as well as Orphan Drug Designation from the European Medicines Agency [4] - Pliant has initiated the BEACON-IPF trial, an adaptive Phase 2b/3 study for bexotegrast in IPF [4] - The company is also conducting a Phase 1 study for PLN-101095, a small molecule targeting solid tumors, and has received regulatory clearance for a Phase 1 study of PLN-101325, a monoclonal antibody for muscular dystrophies [4]

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024. Late Breaker - Oral and ePoster Presentations Title: Evaluation of the ant ...

Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events Statistically significant improvement in alkaline phosphatase (ALP) levels over 24 weeks compared to placebo Continued improvement in hepatocyte function and bile flow by contrast MRI imaging observed from Week 12 to Week 24 SOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced positive 24-week data from the 320 mg co ...

"Steve is a tremendous addition to our board, bringing extensive strategic leadership experience and a depth of financial expertise that will benefit Pliant's continued evolution as a late-stage clinical company," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "Steve's broad financial experience will be highly complimentary to the strong science and business expertise on the board. We look forward to his insights." Pliant Therapeutics is a late-stage biopharmaceutical com ...

SOUTH SAN FRANCISCO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company's newly appointed Senior Vice President of Clinical Development as a material inducement to her employment. The stock options that were granted are subject to an exercise price of $11.51 per share, which is equal to the closing price of t ...

SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held June 5-8, 2024. "We were pleased to share our latest data from our bexotegrast p ...

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024. "Our 2024 ATS presentations include compreh ...

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024. "Our 2024 ATS presentations include compreh ...

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared to placebo Bexotegrast 160 mg was well tolerated over 12 weeks of treatment with no serious adverse events and no discontinuations SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today ann ...